Article Per Year (5 Year)
p-Index From 2019 - 2024
0
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cancer
DENNI JOKO PURWANTO, DENNI JOKO
Unknown Affiliation
Health Professions

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Risiko Kanker Payudara pada Pengguna Obat-obatan Hormonal PURWANTO, DENNI JOKO; REUWPASSA, JAUHARI OKA; ADISASMITA, ASRI C
Indonesian Journal of Cancer Vol 8, No 2 (2014): April-Juni 2014
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Commonly hormonal drugs used by woman are contraceptive and hormone replacement therapy (HRT). A contraceptive user in Indonesia is about 62% aged 16-49 years, modern contraceptive users is 58%. Injected contraception user is 32% followed by oral contraceptive (pill) is 14%. Literature review conducted in this study. The risk use of both hormonal contraception and HRT causing breast cancer still have different opinion The researchers concluded that both of these factors affect the incidence of breast cancer.
Palliative Surgery in Breast Cancer PURWANTO, DENNI JOKO
Indonesian Journal of Cancer Vol 4, No 5 (2010): Workshops 2010
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

https://www.scribd.com/doc/43614373/Palliative-Surgery-in-Breast-Cancer
Preoperative Neoadjuvant Hormonal Therapy and Neoadjuvant Chemotherapy for Stage 3B and 4 Breast Cancer Patients in Dharmais Hospital-National Cancer Center, Indonesia: A Cohort Study Karsono, Ramadhan; Purwanto, Denni Joko; Haryono, Samuel J.; Karsono, Bambang; Sari, Lenny; Pratiwi, Yulia; Aryandono, Teguh
Indonesian Journal of Cancer Vol 12, No 4 (2018): October-December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (891.03 KB) | DOI: 10.33371/ijoc.v12i4.604

Abstract

Background: There are no data of efficacy comparison between primary systemic therapy in stage 3B and 4 breast cancer patients in Indonesia. This study compared long term outcomes of breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT)Methods: This was a cohort study conducted from 2011 to 2017. A total of 122 patients with stage 3B and 4 breast cancer received NAHT (n = 62) or NACT (n = 60) within a 6 cycles for NACT and 6 months for NAHT were included. Patients were excluded if they had a mastectomy before treatment, were pregnant, had been given hormonal therapy or chemotherapy before, had a contra-indication of chemotherapy, had a contra-indication of salpingo-oophorectomy bilateral for premenopausal patients, and declined to enter this study. The primary outcome of this study was overall survival. The outcomes were analysed using Kaplan-Meier for survival analysis and cox proportional hazard regression to estimate the hazard ratio.Results: There was a statistically significant difference in overall survival (p = 0.038). Median overall survival for NAHT patients was 1265 days and for NACT patients was 654 days. The hazard ratio showed NACT patients had a higher risk than NAHT patients (1.7 95% CI 1.03 – 2.9). Pathological complete response rate was higher in the NACT group than in the NAHT group (3.3% vs. 0%).Conclusions: Neoadjuvant hormonal therapy was superior to neoadjuvant chemotherapy in term of overall survival.
Co-Authors Asri C. Adisasmita Bambang Karsono Haryono, Samuel J. JAUHARI OKA REUWPASSA, JAUHARI OKA Karsono, Ramadhan Lenny Sari, Lenny Teguh Aryandono Yulia Pratiwi